Koning Health Achieves MDSAP Certification
August 4, 2026
Certification strengthens Koning’s global regulatory foundation as two new Vera Breast CT systems expand patient access in key U.S. markets
Certification strengthens Koning’s global regulatory foundation as two new Vera Breast CT systems expand patient access in key U.S. markets
Tiny, near-invisible fragments of plastic shed from the products we use every day through sunlight and mechanical wear have been quietly working their way deep into the human body. Microplastics have already been found in the human brain, semen and even the placenta. A recent study investigated how these micro- and nanoplastics (MNPs) might move through the placenta and whether they affect a baby’s development.
Researchers have developed an implant that could deliver next-generation therapies for ovarian cancer precisely where they are needed while simultaneously monitoring how the disease responds.
The DeepHealth Breast Ultrasound system automates the detection, characterisation, and reporting of breast lesions.
GE HealthCare (Nasdaq:GEHC) announced today that it launched its new Invenia ABUS Prime and ABUS StreamVue platforms.
PITTSBURGH, July 29, 2026 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system). Gwyn Lo is a new combined hormonal contraceptive (CHC) patch with low-dose estrogen. The patch has demonstrated contraceptive efficacy for women of childbearing potential with a body mass index (BMI) below 30 kg/m² who are appropriate candidates for CHC. The Gwyn Lo dosage is norelgestromin 220 mcg/day and ethinyl estradiol 20 mcg/day.
Carea, the pregnancy and postnatal wellbeing app, has launched Carea Connect, a service that analyses a woman’s wellbeing data to identify when additional support may be beneficial and proactively connects her with the right maternal health expe
New AI-powered algorithm delivers more personalized birth control by adapting to individual cycle patterns while maintaining established effectiveness rates
Danaher’s (NYSE:DHR) Masimo unit announced today that it received FDA 510(k) clearance for its Patient State Index (PSi) for pediatric patients.
INDIANAPOLIS, July 24, 2026 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cobas® BV/CV (Bacterial vaginosis/Candida vaginitis) assay. This molecular diagnostic test provides results for both Bacterial vaginosis (BV) and Candida vaginitis (CV) from a single vaginal swab sample. It enables accurate and timely results that can lead to improved patient outcomes and enhanced healthcare efficiencies.